ICON4/AGO-OVAR-2.2: Questions about trial design, cost-effectiveness, and clinical benefit [4] (multiple letters)

Lancet

Volumn 362, Issue 9392, 2003, Pages 1333-1334

  Wheatley, Keith ^a   Gray, Richard ^a   Newman, Geoff ^b   Green, John A ^c   Colombo, Nicoletta ^d   Du Bois, Andreas ^e   Kristensen, Gunnar ^f   Ledermann, Jonathan ^g   Torri, Valter ^h  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Sussex Cancer Centre ^*  (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ALOPECIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; HUMAN; LETTER; META ANALYSIS; NAUSEA; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; METHODOLOGY; MORTALITY; OVARIAN NEOPLASMS; STANDARDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142155203     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14601-6     Document Type: Letter

References (0)